Jacobs & Co. CA Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Jacobs & Co. CA increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,050 shares of the biopharmaceutical company's stock after purchasing an additional 859 shares during the quarter. Jacobs & Co. CA's holdings in Regeneron Pharmaceuticals were worth $6,374,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Avalon Trust Co acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Finally, Crowley Wealth Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $112.15 during trading hours on Friday, hitting $493.24. 6,307,887 shares of the stock were exchanged, compared to its average volume of 829,478. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock's 50-day moving average price is $584.25 and its two-hundred day moving average price is $667.42. The company has a market cap of $53.25 billion, a price-to-earnings ratio of 12.89, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 12-month low of $485.00 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $9.55 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.71%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on REGN. TD Cowen decreased their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, Truist Financial decreased their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $874.56.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.